Sagittarius Life Science

Sagittarius Life Science FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sagittarius Life Science (3205.TWO) as of Oct 31, 2026 is 73.54 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 99.48 % — a change of -26.08% (lower).

FCF Conversion

73.54 %

YoY

-26.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sagittarius Life Science is 2025 73.54 % . FCF Conversion Rate (FCF/EBITDA) of Sagittarius Life Science was 2024 99.48 % . It decreases by -26.08% lower compared to the previous year.

The Sagittarius Life Science FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
63.13 TWD
Jan 1, 2019
99.73 TWD
Jan 1, 2020
99.09 TWD
Jan 1, 2021
43.52 TWD
Jan 1, 2022
72.75 TWD
Jan 1, 2023
129.69 TWD
Jan 1, 2024
99.48 TWD
Jan 1, 2025
73.54 TWD
The Sagittarius Life Science FCF Conversion history
YEARFCF ConversionYoY
73.54 %-26.08%
99.48 %-23.29%
129.69 %+78.26%
72.75 %+67.17%
43.52 %-56.08%
99.09 %-0.64%
99.73 %+57.97%
63.13 %+175.00%
22.96 %-81.92%
127.00 %+62.52%
78.15 %-85.55%
540.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sagittarius Life Science Stock analysis

What does Sagittarius Life Science do? Sagittarius Life Science Corp. generates revenue through the manufacture and sale of Chinese and western medicine, including nutrition and health formulations, natural and organic food, beverages, probiotic fermentation products, beauty care ingredients, Chinese herbal medicines, plant new medicines, and health supplies. The company serves domestic markets in Taiwan and overseas markets in Asia and the Americas, distributing its products through established channels. Technical services for pharmaceutical R&D are also a key revenue stream, supporting clients in developing both traditional and modern medicine solutions. The firm's product portfolio targets health-conscious consumers seeking natural and organic solutions, as well as businesses in the pharmaceutical and beauty care industries requiring specialized ingredients and formulations. Domestic sales focus on Taiwan, while international distribution extends to Asian regions outside of Taiwan and the Americas, reflecting a strategic market expansion. Revenue is derived from direct product sales and technical service contracts, with no mention of third-party partnerships or additional revenue streams beyond the described offerings. Sagittarius Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sagittarius Life Science stock

FCF Conversion Rate (FCF/EBITDA) of Sagittarius Life Science is 73.54 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Sagittarius Life Science changed from 99.48 % to 73.54 %, representing a -26.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sagittarius Life Science since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sagittarius Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Sagittarius Life Science

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Sagittarius Life Science